Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

Sjögren’s antibody testing is done using a blood sample. It checks antibody levels, including anti-SS-A (also called anti-Ro) and anti-SS-B (also called anti-La). Anti-SS-A and anti-SS-B are ...

If you’re on the fence about investing in Regeneron Pharmaceuticals ... TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a ...

If you’re on the fence about investing in Regeneron Pharmaceuticals ... an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 ...

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...